These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 19817997)
1. The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. Gurbel PA; Bliden KP; Antonino MJ; Stephens G; Gretler DD; Jurek MM; Pakyz RE; Shuldiner AR; Conley PB; Tantry US J Thromb Haemost; 2010 Jan; 8(1):43-53. PubMed ID: 19817997 [TBL] [Abstract][Full Text] [Related]
2. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study. Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612 [TBL] [Abstract][Full Text] [Related]
3. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. Gladding P; Webster M; Zeng I; Farrell H; Stewart J; Ruygrok P; Ormiston J; El-Jack S; Armstrong G; Kay P; Scott D; Gunes A; Dahl ML JACC Cardiovasc Interv; 2008 Dec; 1(6):620-7. PubMed ID: 19463375 [TBL] [Abstract][Full Text] [Related]
4. Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity. The result of the ACCEL-DIP Study. Park Y; Jeong YH; Tantry US; Ahn JH; Kim KH; Koh JS; Park JR; Hwang SJ; Kwak CH; Hwang JY; Gurbel PA Thromb Haemost; 2014 Dec; 112(6):1198-208. PubMed ID: 25182660 [TBL] [Abstract][Full Text] [Related]
5. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617 [TBL] [Abstract][Full Text] [Related]
6. The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. Gurbel PA; Shuldiner AR; Bliden KP; Ryan K; Pakyz RE; Tantry US Am Heart J; 2011 Mar; 161(3):598-604. PubMed ID: 21392617 [TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Giusti B; Gori AM; Marcucci R; Saracini C; Sestini I; Paniccia R; Valente S; Antoniucci D; Abbate R; Gensini GF Pharmacogenet Genomics; 2007 Dec; 17(12):1057-64. PubMed ID: 18004210 [TBL] [Abstract][Full Text] [Related]
8. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. Siller-Matula JM; Delle-Karth G; Lang IM; Neunteufl T; Kozinski M; Kubica J; Maurer G; Linkowska K; Grzybowski T; Huber K; Jilma B J Thromb Haemost; 2012 Apr; 10(4):529-42. PubMed ID: 22260716 [TBL] [Abstract][Full Text] [Related]
9. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. Saucedo JF; Angiolillo DJ; DeRaad R; Frelinger AL; Gurbel PA; Costigan TM; Jakubowski JA; Ojeh CK; Duvvuru S; Effron MB; Thromb Haemost; 2013 Feb; 109(2):347-55. PubMed ID: 23223867 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. Angiolillo DJ; Welsh RC; Trenk D; Neumann FJ; Conley PB; McClure MW; Stephens G; Kochman J; Jennings LK; Gurbel PA; Wójcik J; Dabrowski M; Saucedo JF; Stumpf J; Buerke M; Broderick S; Harrington RA; Rao SV Circ Cardiovasc Interv; 2012 Jun; 5(3):347-56. PubMed ID: 22619259 [TBL] [Abstract][Full Text] [Related]
11. Relationship between CYP2C19 loss-of-function polymorphism and platelet reactivities with clopidogrel treatment in Japanese patients undergoing coronary stent implantation. Nakata T; Miyahara M; Nakatani K; Wada H; Tanigawa T; Komada F; Hoshino K; Aoki T; Nishimura Y; Tamaru S; Ito M; Nishikawa M; Circ J; 2013; 77(6):1436-44. PubMed ID: 23470885 [TBL] [Abstract][Full Text] [Related]
12. Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. Ueno M; Ferreiro JL; Desai B; Tomasello SD; Tello-Montoliu A; Capodanno D; Capranzano P; Kodali M; Dharmashankar K; Charlton RK; Bass TA; Angiolillo DJ JACC Cardiovasc Interv; 2012 Mar; 5(3):293-300. PubMed ID: 22440495 [TBL] [Abstract][Full Text] [Related]
13. Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting. Bouman HJ; Harmsze AM; van Werkum JW; Breet NJ; Bergmeijer TO; Ten Cate H; Hackeng CM; Deneer VH; Ten Berg JM Heart; 2011 Aug; 97(15):1239-44. PubMed ID: 21628721 [TBL] [Abstract][Full Text] [Related]
14. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. Bouman HJ; Parlak E; van Werkum JW; Breet NJ; ten Cate H; Hackeng CM; ten Berg JM; Taubert D J Thromb Haemost; 2010 Mar; 8(3):482-8. PubMed ID: 20040042 [TBL] [Abstract][Full Text] [Related]
15. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients. Namazi S; Kojuri J; Khalili A; Azarpira N Biochem Pharmacol; 2012 Apr; 83(7):903-8. PubMed ID: 22265638 [TBL] [Abstract][Full Text] [Related]
16. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. Brandt JT; Close SL; Iturria SJ; Payne CD; Farid NA; Ernest CS; Lachno DR; Salazar D; Winters KJ J Thromb Haemost; 2007 Dec; 5(12):2429-36. PubMed ID: 17900275 [TBL] [Abstract][Full Text] [Related]
17. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent. Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW Thromb Res; 2011 Oct; 128(4):352-7. PubMed ID: 21621250 [TBL] [Abstract][Full Text] [Related]
18. The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention. Hwang SJ; Jeong YH; Kim IS; Koh JS; Kang MK; Park Y; Kwak CH; Hwang JY Thromb Res; 2011 Jan; 127(1):23-8. PubMed ID: 21075428 [TBL] [Abstract][Full Text] [Related]
19. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. Aleil B; Jacquemin L; De Poli F; Zaehringer M; Collet JP; Montalescot G; Cazenave JP; Dickele MC; Monassier JP; Gachet C JACC Cardiovasc Interv; 2008 Dec; 1(6):631-8. PubMed ID: 19463377 [TBL] [Abstract][Full Text] [Related]
20. Association of CYP2C19 genotype with periprocedural myocardial infarction after uneventful stent implantation in Chinese patients receiving clopidogrel pretreatment. Wu H; Qian J; Sun A; Wang Q; Ge J Circ J; 2012; 76(12):2773-8. PubMed ID: 22971905 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]